Welcome to our dedicated page for Blueprint Medicines SEC filings (Ticker: BPMC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Blueprint Medicines Corp. filings document the company’s biopharmaceutical issuer history, common stock registration, governance votes and corporate-status reporting. Recent Form 8-K disclosures include annual meeting matters such as director elections and advisory executive compensation votes, while Form 15 records the termination of registration or suspension of Exchange Act reporting duties for the company’s common stock.
The filing record also reflects capital-structure disclosure, stockholder voting procedures, registered-security information and material-event reporting associated with Blueprint Medicines’ public-company obligations.
Blueprint Medicines Corp (BPMC) director Lynn Seely received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, with a value of $128.12 per unit. Following this transaction, Seely's direct ownership increased to 17,156 shares.
Key terms of the RSU grant:
- 100% vesting occurs at the earlier of June 18, 2026, or the next annual stockholder meeting
- Each RSU represents a contingent right to receive one share of common stock
- Total grant value: approximately $500,000
This Form 4 filing, submitted by attorney-in-fact Melissa Masse on June 23, 2025, reflects standard director compensation practices through equity grants. The transaction was reported within the required SEC filing deadline of two business days.
Blueprint Medicines Director Daniella Beckman received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, with a value of $128.12 per unit, bringing her total direct holdings to 14,744 shares.
The RSUs have specific vesting terms: they will vest 100% on either June 18, 2026 or the next annual stockholder meeting, whichever occurs first. Each RSU represents the right to receive one share of common stock upon vesting.
This Form 4 filing, submitted by Attorney-in-Fact Melissa Masse on June 23, 2025, reflects standard equity compensation for a board member, indicating continued alignment between director and shareholder interests. The transaction was executed under regular compensation arrangements rather than through a Rule 10b5-1 trading plan.
Blueprint Medicines Corp (BPMC) director Alexis Borisy received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, at a price of $128.12 per share. Following this transaction, Borisy directly owns 78,062 shares of the company.
Key details of the RSU grant:
- Vesting occurs at 100% of underlying shares on the earlier of: - June 18, 2026 - Next annual stockholders' meeting
- Each RSU represents a contingent right to receive one share of common stock
- Transaction was reported via Form 4 filing on June 23, 2025
This equity grant appears to be part of the company's director compensation program, aligning the director's interests with those of shareholders through stock ownership.
Blueprint Medicines Director Habib J. Dable received a grant of 3,902 restricted stock units (RSUs) on June 18, 2025, at a reference price of $128.12 per share. Following this transaction, Dable directly owns 12,644 shares of the company.
Key details of the RSU grant:
- Vesting occurs 100% on the earlier of June 18, 2026, or the next annual stockholder meeting
- Each RSU represents the right to receive one share of common stock upon vesting
- The transaction was reported via Form 4 filing, indicating changes in beneficial ownership
This equity grant appears to be part of the company's director compensation program, aligning the director's interests with those of shareholders through stock ownership. The filing was signed by Melissa Masse as attorney-in-fact on June 23, 2025.
Blueprint Medicines Corporation (BPMC) – Form 4 filed 23 Jun 2025
Director Lonnel Coats disclosed the award of 3,902 restricted stock units (RSUs) on 18 Jun 2025. Each RSU represents one share of common stock and vests 100 % on the earlier of 18 Jun 2026 or the company’s next annual meeting. No cash consideration was paid; the transaction is coded “A” (acquisition) and reflects routine director compensation rather than an open-market purchase.
Following the grant, Coats’ direct beneficial ownership increased to 6,144 BPMC shares, implying a net addition of 3,902 shares relative to his prior holding. No derivative securities, sales, or additional purchases were reported.
The filing is administrative in nature, providing insight into insider equity alignment but offering no new financial, operational, or strategic information about Blueprint Medicines. Investors may view the added ownership as modestly positive for governance alignment, yet the impact on valuation is likely immaterial.
Blueprint Medicines Corporation (BPMC) – SEC Form 4 Insider Transaction
Director John Tsai reported the receipt of 3,902 restricted stock units (RSUs) on 18 June 2025. Each RSU represents one share of BPMC common stock and vests 100 % on the earlier of 18 June 2026 or the company’s next annual shareholders’ meeting. The grant was recorded at an indicated price of $128.12 per share, a value reference supplied within the Form 4. Following the award, Tsai’s total direct beneficial ownership stands at 12,644 shares.
No open-market purchases or sales, option exercises, or derivative transactions were disclosed. The filing indicates a routine equity compensation grant intended to align the director’s interests with those of shareholders.
On 18 June 2025, Blueprint Medicines Corporation (Nasdaq: BPMC) reported the results of its 2025 Annual Meeting of Stockholders (Form 8-K, Item 5.07).
- Board elections: Class I directors Jeffrey W. Albers (44,683,223 for / 15,507,415 withheld ≈ 74%), Mark Goldberg, M.D. (46,734,594 / 13,456,044 ≈ 78%), and John Tsai, M.D. (47,572,890 / 12,617,748 ≈ 79%) were elected to three-year terms ending at the 2028 meeting.
- Say-on-pay: Executive compensation received strong support, passing with 57,714,069 votes for (≈96%), 2,450,825 against, and 25,744 abstentions.
- Auditor ratification: Ernst & Young LLP was re-appointed as independent auditor for FY 2025 with 62,209,853 votes for (≈99.5%), 288,580 against, and 34,861 abstentions.
No additional matters were presented. The filing is routine, reflecting continued shareholder endorsement of management and governance practices without introducing new strategic or financial information.